Discover 764 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 764
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
for
Urothelial Cancer
Location: Washington D.C. DC, Baltimore MD, Charlottesville VA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07106762
Phase2, Phase3, Recruiting
Pediatric Radiation Therapy Registry
for
Sarcoma, Pediatric Brain Tumors
Location: Washington D.C. DC, Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sex: All
Age: 0 - 26
Code: NCT07129317
Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
for
Recurrent Non-Muscle Invasive Bladder Carcinoma,
Location: Washington D.C. DC, Baltimore MD, Frederick MD,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT07000084
Phase3, Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
for
Multiple Myeloma
Location: Washington D.C. DC, Baltimore MD, Newark DE,
Sponsor: European Myeloma Network B.V.
Sex: All
Age: 18+
Code: NCT05243797
Phase3, Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma,
Location: Washington D.C. DC, Harrisburg PA, Sewell NJ,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT04566328
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
for
Biochemically Recurrent Prostate Carcinoma,
Location: Washington D.C. DC, Bethesda MD, Baltimore MD, York PA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: Male
Age: 18+
Code: NCT04423211
Phase3, Recruiting
Blue Light Cystoscopy With Cysview® Registry
for
Bladder Cancer
Location: Washington D.C. DC, Baltimore MD, New York NY,
Sponsor: Photocure
Sex: All
Age: 18+
Code: NCT02660645
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase3, Recruiting
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
for
Bladder Cancer
Location: Washington D.C. DC, Baltimore MD
Sponsor: Johns Hopkins University
Sex: All
Age: 18+
Code: NCT06525571
Phase3, Recruiting
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
for
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer,
Location: Washington D.C. DC, Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sex: All
Age: 18+
Code: NCT05312671
Phase2, Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
for
Classic Follicular Lymphoma,
Location: Washington D.C. DC, Bethesda MD, Baltimore MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06337318
Phase3, Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Washington D.C. DC, Bethesda MD, Baltimore MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04269902
Phase3, Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Washington D.C. DC, Media PA, Paoli PA, Wynnewood PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase2, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Janssen Research & Development, LLC
Sex: Male
Age: 18+
Code: NCT07164443
Phase3, Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
for
Carcinoma, Non-small-Cell Lung
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05498428
Phase2, Recruiting
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
for
Neoplasms, Cancer, Caregiver
Location: Washington D.C. DC
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
A Study to Evaluate the Raindrop Near Vision Inlay Under Flap or Within Pocket
for
Presbyopia
Location: Washington DC
Sponsor: Whitten Laser Eye
Sex: All
Age: 40 - 70
Code: NCT03376412
Recruiting
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation